HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Google Scholar Articles by Burmeister Getz, E. Articles by Fuller, R. PubMed PubMed Citation Articles by Burmeister Getz, E. Articles by Fuller, R. Social Bookmarking                         What's this?

Human Pharmacokinetics/Pharmacodynamics of an Interleukin-4 and Interleukin-13 Dual Antagonist in Asthma

From Aerovance, Inc, Berkeley, California (Dr Burmeister Getz, Dr Fuller) and The "P Less Than" Company, San Francisco, California (Dr Fisher).

Pitrakinra, a 15-kDa recombinant human interleukin-4 mutein, targets allergic Th2 inflammation by competitively binding to interleukin-4 receptor alpha to interfere with interleukin-4 and interleukin-13 action. The authors characterized pitrakinra pharmacokinetics using data from 96 atopic patients, then compared pharmacokinetics with pharmacological response in asthma following subcutaneous versus inhalation dosing. A 1-compartment systemic model with site-specific absorption describes pitrakinra pharmacokinetics following subcutaneous, nebulization, and inhalation powder delivery. Typical CL/F and V/F, referenced to subcutaneous administration, are 15.5 L/h and 67.5 L, yielding a 3.0-hour half-life of plasma decline. Absorption into the blood (half-life 1.0 hour, lag 18 minutes) is more rapid than elimination. Relative to subcutaneous injection, systemic availability of the first inhaled dose is 3%. Subcutaneous injection produced variable efficacy despite high systemic exposure, suggesting inadequate exposure at the site of action in some participants. Inhalation produced consistent pharmacodynamic response despite low systemic exposure. The lung appears as the primary site of pitrakinra's antiasthmatic action, supporting direct administration to the lung for the treatment of asthma.

Key Words: Asthma • pitrakinra • pharmacokinetics • interleukin-4 • interleukin-13

Address for reprints: Elise Burmeister Getz, PhD, Oriel Therapeutics, Inc, 2600 10th Street, Berkeley, CA 94710; e-mail: EGetz{at}orieltherapeutics.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?